Abstract Purpose: The therapeutic efficacy of a unique melanoma-targeting peptide conjugated with an in vivo generated a-particle-emitting radionuclide was evaluated in the B16/F1mouse melanoma animal model. a-Radiation is densely ionizing, resulting in high concentrations of destructive radicals and irreparable DNA double-strand breaks. This high linear energy transfer overcomes radiation-resistant tumor cells and oxygen effects resulting in potentially high therapeutic indices in tumors such as melanoma. 
)CCMSH significantly decreased tumor growth rates resulting in extended mean survival times, and in many cases, complete remission of disease. 212 Pb-DOTA-Re(Arg 11 )CCMSH seems to be a very promising radiopharmaceutical for targeted radionuclide therapy of melanoma.
The incidence and mortality rates associated with melanoma have increased by 3% to 7% in recent years (1, 2) . Early melanoma tumor diagnosis and prompt surgical removal are a patient's best hope for a cure. Unfortunately, metastatic melanoma is resistant to current chemotherapy and immunotherapy regimens. Survival times for patients with lymph node metastases average 12 to 15 months, whereas patients with liver and bone metastases average 3 to 4 months (1). Despite extensive research, there have been no major improvements in advanced melanoma treatment outcomes during the past 30 years. Targeted radionuclide therapy, namely a-particle therapy, is a potentially important alternative to conventional therapeutic regimens. In comparison with external beam radiation therapy and chemotherapy, targeted radionuclide therapy offers the potential of tumor-selective radiotherapeutic treatment of distal metastases whereas sparing normal tissues and organs.
a-Particles are doubly-charged helium ions with energies of 5 to 9 MeV characterized by high linear energy transfer over short path lengths refs. 3, 4) . Only a few a-particle traversals per cell are necessary to cause irreversible damage resulting in cell death (5) . Cytotoxicity of a-particle radiation is independent of dose rate (4) and unaffected by tissue oxygen levels (6) , which allow tumors with hypoxic regions to be effectively irradiated. The short range and high ionization density associated with a-particles contribute to highly specific destruction within tumors, whereas minimizing collateral damage of healthy tissues. Promising preclinical a-particle radioimmunotherapy results with leukemia (7, 8) lung (9) , ovarian (10) , and prostate cancers (11) have been shown. In addition, early clinical trials have highlighted the potential of 213 Bi and 211 At labeled immunoconjugates for a-radiotherapy (12, 13) .
Over the past several years, our laboratory has developed a novel class of metal-cyclized melanotropin peptide analogues for melanoma imaging and therapy that target the melanocortin-1 receptor, which is overexpressed on melanoma tumor cells (14 -16) . Incorporation of a rhenium metal atom into the structure of the cyclic melanotropin peptide resulted in resistance to chemical and proteolytic degradation in vivo, whereas retaining high bioactivities. In this study, we report the melanoma therapeutic effects of targeted a-particle radiotherapy using the 1,4,7,10-tetraazacyclodecane- 11 )CCMSH yielded a dose-dependent reduction in tumor growth and total eradication of many tumors at higher activity levels. Despite being classified as a radiation-resistant neoplasm, melanoma was efficaciously treated by peptide-targeted a-radiation in tumor-bearing mice, highlighting the clinical potential of targeted a-radiotherapy for disseminated melanoma.
Materials and Methods

Synthesis of
212 Pb-DOTA-Re(Arg 11 )CCMSH. DOTA-Re(Arg 11 )-CCMSH, was synthesized and purified by a method previously described (17 11 )CCMSH in tumor and normal organs and tissues using methods described previously (20 -22) . Time-activity curves were generated for 13 organs and tissues (blood, brain, heart, lung, liver, spleen, stomach, kidney, large intestine, small intestine, muscle, pancreas, and tumor). Cumulative activities of 212 Pb and 212 Bi were determined for each organ by integrating the area under the time-activity curves. The cumulative activities were then used with a dosimetric model (21, 22) developed specifically for the laboratory mouse, accounting for the a-and h-radiation deposited locally. The dosimetric model is used to evaluate dose from activity within tissues as well as the cross-organ h dose contributions.
Radionuclide therapy of Pb-DOTA-Re(Arg 11 )CCMSH through the tail vein on the 4th day after tumor cell implantation. An untreated tumor control group received 100 AL of normal saline. After the administration of the therapeutic infusion, tumor size, body weight, and animal body condition were determined daily. Tumor volume was calculated by measuring the length, width, and depth of the tumors with a caliper and using the following formula: tumor volume = (length Â width Â depth) Â k / 6. Mice were removed from the therapy study and sacrificed if body weight loss was >20% of initial body weight, tumor size exceeded 1.0 cm 3 , or the appearance of skin ulcerations at the tumor site. The total study period was 120 days, which was 10 times the average survival period of untreated tumor-bearing animals. Toxicity of 212 Pb-DOTA-Re(Arg 11 )CCMSH to the kidneys of 100 and 200 ACi treatment groups was evaluated by pathologic examination after completion of the therapy study. The kidney and tumor site skin biopsies from therapy animals were examined by a veterinary pathologist at the University of Missouri School of Veterinary Medicine Research Animal Diagnostic Laboratory. Kaplan-Meier survival curves were obtained by using SPSS software (SPSS Inc., Chicago, IL). Statistical analysis was done using Student's t test for unpaired data. A 95% confidence level was chosen to determine the significance between untreated and treated groups, with P < 0.05 being significantly different. 208 Pb, yielding an a-particle and several h and g emissions (3, 4 Pb-DOTARe(Arg 11 )CCMSH was very rapid, with f90% of the administered radioactivity washed out of the body by 2 hours postinjection. Very little radioactivity remained in blood and major organs at 2 hours postinjection, including the liver, lung, and muscle except for the kidneys, which was the primary route of excretion for 212 Pb-DOTA-Re(Arg 11 )CCMSH. Coinjection of NDP did not affect kidney uptake, and therefore the kidney activity was likely due to nonspecific peptide retention. Biodistribution results of the radiolabeled peptide, monitored in the 212 Pb and 212 Bi energy windows, was not significantly different with respect to radioactivity uptake and retention in the tumor and major organs including the kidneys (data not shown).
Results
DOTA-
The absorbed radiation doses to tumor and normal organs from 212 Pb-DOTA-Re(Arg 11 )CCMSH were estimated in this study based on the biodistribution data in B16/F1 murine melanoma -bearing mice ( Pb-DOTA-Re(Arg 11 )CCMSH treatment on tumor growth rate and mean body weight of the mice in the therapy study are shown in Fig. 2A and B, respectively. Single-dose administrations of 50, 100, and 200 ACi of 212 Pb-DOTA-Re(Arg 11 )CCMSH caused substantial tumor growth inhibition over the time period of the therapy study compared with the untreated tumor control group ( Fig. 2A) . Treated mice maintained healthy physical appearances (without diarrhea and scruff coat), normal activity levels and weight gain throughout the study period (Fig. 2B) . Tumor response to 212 Pb-DOTA-Re(Arg 11 )CCMSH treatment was dosedependent. Decreases in tumor growth rates were more pronounced for the 100 ACi treatment group compared with the 50 ACi treatment group. Two of 10 mice in the 100 ACi treatment group were tumor-free at the completion of the 120-day study. The treatment group receiving the 200 ACi single dose of 212 Pb-DOTA-Re(Arg 11 )CCMSH exhibited the best overall tumor growth inhibition ( Fig. 2A) . Four of nine mice in the 200 ACi treated group survived the 120-day study tumor-free, whereas two of the nine mice displayed a partial tumor remission response at 35 and 55 days (Fig. 3) . The mean survival time for the untreated tumor control group was 14.6 F 4.4 days. The 50 ACi treated group exhibited a mean survival time of 22.0 F 5.5 days, which was significantly longer than the untreated tumor control group (P = 0.004, Fig. 3 ). Mean survival times of tumor mice in the 100 and 200 ACi treatment groups that did not survive the entire study were significantly extended to 28.0 F 8.8 (P = 0.002) and 49.8 F 27.3 days (P = 0.02), respectively (Fig. 3) . After completion of the therapy study, the kidneys and tumor implantation sites of the treated mice that survived the study were examined. Histopathologic examination showed evidence of moderate kidney toxicity, with a thinner than normal renal cortex and damage to glomeruli and tubular structures despite lack of observational effects during the study period (Fig. 4) . No evidence of secondary tumor formation was found on necropsy. Biopsies of tumor implantation sites revealed the presence of macrophage infiltrates, but no melanoma cells. Staining for the melanoma antigen S100 was also negative, indicating that the mice that survived the study were tumor-free.
Discussion
In this study, the pharmacokinetics and therapeutic efficacy of 212 Pb-labeled DOTA-Re(Arg 11 )CCMSH were determined in B16/F1 murine melanoma -bearing mice. The decay scheme of 212 Pb includes 212 Bi, which yields an a-particle, two h-particles, and several g-emissions upon decay. a-Particle emitters are particularly attractive for targeted radiotherapy due to high linear energy transfer properties such as localized dense ionization, which results in irreparable DNA double-strand breaks and cytotoxicity that is independent of tissue oxygen content or dose rate (3 Pb, internalized and retained by tumor cells decays to the a-particle emitting 212 Bi, localizing the highly toxic short-range a-radiation within the tumor. This strategy is referred to as an in vivo generator approach that produces a high dose delivery to the targeted melanoma tumor cells, whereas resulting in lower nonspecific irradiation to normal tissue. Moreover, the short half-life of Pb-DOTA-Re(Arg 11 )CCMSH had high receptor-mediated tumor uptake and prolonged retention. Disappearance of activity from the normal organs and tissues was rapid. The majority of the administered activity was cleared through the kidneys, with f90% of the injected dose being excreted in the urine by 2 hours postinjection. As seen with other radiolabeled peptides, disappearance of activity from the kidneys was slower than the other major organs. Coinjection of excess nonradioactive NDP-MSH peptide dramatically reduced tumor uptake but did not affect radioactivity in the kidneys, demonstrating that the kidney radioactivity is nonspecific and not mediated by MC1 receptor interaction. The infusion of lysine or arginine, prior to or with dose administration, has been successful in reducing nonspecific retention of activity in the kidneys (24) . Coinjection of free lysine or arginine in this instance, however, did not affect kidney radioactivity levels of 212 Pb-DOTA-Re(Arg 11 )CCMSH. Changing lysine 11 to arginine in the CCMSH peptide significantly increased its tumor uptake and reduced its kidney retention (25) . However, the amino acid substitution also eliminated additional suppression of nonspecific kidney uptake of radioactivity by lysine or arginine coinfusion. It is possible that radioactivity in the kidneys may be due to free 212 Bi, due to transient oxidation states of the resulting bismuth that occur during the conversion process (26) . Normal tissue toxicity of a-particle emitting radionuclides is a concern due to the high cytotoxicity of a-radiation. Dosimetry results showed that the tumor received the highest dose followed by the kidneys and blood. The toxicity of 212 Bi circulating in blood is unlikely to be significant due to the short path length of a-radiation and short resonance time. However, radioactivity residing in the kidney may result in renal toxicity. Acute radiation nephritis was reported in Cynomolgus monkeys treated with escalating doses of an a-particle emitting 225 Ac-HuM195 monoclonal antibody complex (27) . Estimated kidney doses of 9 to 13 Gy to the renal cortex from 225 Ac and its a-particle-emitting daughters, including 213 Bi, resulted in tubular epithelial necrosis and marked regeneration. Accumulation of 213 Bi or 212 Bi in the kidneys was consistent with biodistribution studies of nonchelated or free radiobismuth (28) .
Intravital chelation of 212
Bi has been one method proposed to reduce radioactivity in the kidneys. DMPS intravital chelation of free 212 Bi generated by circulating 212
Pb radiolabeled antibodies was shown to reduce bismuth activity in the kidneys (29) . The extended circulation time of the 212 Pb radiolabeled antibodies would allow ample time for the generation of free 212 Bi in vivo, allowing an intravital chelation strategy to be effective. However, the rapid pharmacokinetics of small radiolabeled peptides dramatically minimizes the amount of free 212 Bi generated in vivo. Two hours postinjection, f90% of the injected dose was in the urine, with the majority of the remaining activity sequestered in the tumor. It is unlikely that 212 Bi freed during circulation will contribute significantly to the kidney dose because the residence time of the radiolabeled peptide in the blood is very short. Tumor and normal organ uptake and retention of radiolabeled DOTA-Re(Arg 11 Table 1 , showed that there was no significant difference in tumor retention of activity in vivo during the first 4 hours postinjection, whereas activity levels in the blood dropped rapidly. If activity was effluxing from the tumor, one would expect decreasing activity levels in the tumor over the first 4 hours after dose administration. Radiobismuth deposition in the kidneys is more likely to arise from nonspecific retention of radiolabeled peptide or injection of 212 Bi generated during peptide labeling and purification. Bismuth-212 generated before injection can be effectively chelated by the addition of diethylenetriaminepentaacetic acid or EDTA to the dose immediately prior to administration. Modification of the linkage between the peptide and DOTA moieties in 212 Pb-DOTA-Re(Arg 11 )CCMSH is likely to reduce renal retention of the radiolabeled peptide. The Pb-DOTARe(Arg 11 )CCMSH can be reduced by employing the same strategy in the future investigations. Furthermore, a multipledose radiotherapy regimen may result in a lower kidney dose, whereas maintaining high therapeutic efficacy (31 -34) .
The therapeutic efficacy of peptide-targeted a-therapy was greater than peptide-targeted 188 Re h-emitter therapy in the B16/F1 solid tumor melanoma mouse model (31) . Tumorbearing mice treated with single 200 or 600 ACi doses of 188 Re-(Arg 11 )CCMSH complex exhibited no improvement in mean survival over the non -treatment control group. Only mice treated with 2 Â 400 ACi doses of 188 Re-(Arg 11 )CCMSH displayed an improvement in mean survivability. However, there were no complete remissions or durable cures. In the 212 Pb-DOTA-Re(Arg 11 )CCMSH therapy studies reported here, all treated groups of melanoma mice exhibited significant (P < 0.05, Fig. 3 ) improvement in mean survival over the nontreatment control group. Moreover, 20% and 45% of the mice receiving 100 or 200 ACi of 212 Pb-DOTA-Re(Arg 11 )CCMSH survived the study disease-free. The differences in therapeutic efficacies are likely due to the differences in radiation decay properties and tumor size. Rhenium-188 is a high-energy h-emitter, which may have resulted in much of its radiation being deposited outside the tumor volume. High-energy h-emitters, such as 188 Re and 90 Y, are probably better suited for large tumor volumes, as exemplified by targeted radiotherapy with radiolabeled octreotide analogues (35) .
In this study, 212 Pb-DOTA-Re(Arg 11 )CCMSH treatment significantly decreased tumor growth rates and extended the mean survival time of melanoma-bearing mice in the B16/F1 murine melanoma model. Targeted radiotherapy with short path length high -linear energy transfer 212 Bi a-particles focused energy deposition within tumor cells yielding dramatic improvements in melanoma therapeutic efficacies.
212 Pb-DOTA-Re(Arg 11 )CCMSH seems to be a very promising radiopharmaceutical for targeted radionuclide therapy of melanoma.
